Impaired leptin response to glucocorticoid as a chronic complication of diabetes

Samuel Dagogo-Jack, Jianmei Liu, Hasan Askari, Gunjan Tykodi, Indira Umamaheswaran

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Leptin has anorectic, anti-obesity, and insulin-sensitizing properties. We recently reported subnormal responses to the leptin secretagogue dexamethasone in diabetes (DM). To determine whether this defect precedes or follows the occurrence of diabetes, we have studied 37 adults: 11 with type 2 DM diagnosed within 6 months prior to study, 16 with chronic (≥20 years) DM, and 10 healthy controls. After baseline measurements, subjects ingested dexamethasone (4 mg), followed by blood sampling 16 and 40 h later. Nadir plasma cortisol levels (<2.5 mg/dl) occurred 16 h after dexamethasone ingestion in all study groups; this period of maximal biological action of dexamethasone was associated with peak plasma leptin levels. The peak dexamethasone-stimulated plasma leptin responses (% baseline, ±SEM) were 188±18.7% among healthy controls, 180±13.8% among new DM patients, and 127±10.5% (P<0.01) in chronic DM patients. Following dexamethasone ingestion, plasma glucose remained stable in the control and new DM groups but increased by 240% in the chronic DM patients; in contrast, plasma insulin increased significantly in controls and new DM patients but not in patients with chronic DM. These results indicate that plasma leptin responses to secretagogue are preserved in newly diagnosed diabetes patients but markedly attenuated in patients with long-standing diabetes, who also were unable to augment insulin secretion during glucocorticoid treatment. Thus, defective glucocorticoid augmentation of plasma leptin, probably related to β-cell failure, may be a novel chronic complication of diabetes. Theoretically, such a defect could contribute to the obesity and insulin resistance associated with diabetes. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)327-332
Number of pages6
JournalJournal of Diabetes and its Complications
Volume14
Issue number6
DOIs
StatePublished - Dec 16 2000
Externally publishedYes

Fingerprint

Diabetes Complications
Leptin
Glucocorticoids
Dexamethasone
Insulin
Obesity
Eating
Appetite Depressants
Insulin Resistance
Hydrocortisone
Glucose

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Impaired leptin response to glucocorticoid as a chronic complication of diabetes. / Dagogo-Jack, Samuel; Liu, Jianmei; Askari, Hasan; Tykodi, Gunjan; Umamaheswaran, Indira.

In: Journal of Diabetes and its Complications, Vol. 14, No. 6, 16.12.2000, p. 327-332.

Research output: Contribution to journalArticle

Dagogo-Jack, Samuel ; Liu, Jianmei ; Askari, Hasan ; Tykodi, Gunjan ; Umamaheswaran, Indira. / Impaired leptin response to glucocorticoid as a chronic complication of diabetes. In: Journal of Diabetes and its Complications. 2000 ; Vol. 14, No. 6. pp. 327-332.
@article{a9197a836185430696d9b2c5830efa0c,
title = "Impaired leptin response to glucocorticoid as a chronic complication of diabetes",
abstract = "Leptin has anorectic, anti-obesity, and insulin-sensitizing properties. We recently reported subnormal responses to the leptin secretagogue dexamethasone in diabetes (DM). To determine whether this defect precedes or follows the occurrence of diabetes, we have studied 37 adults: 11 with type 2 DM diagnosed within 6 months prior to study, 16 with chronic (≥20 years) DM, and 10 healthy controls. After baseline measurements, subjects ingested dexamethasone (4 mg), followed by blood sampling 16 and 40 h later. Nadir plasma cortisol levels (<2.5 mg/dl) occurred 16 h after dexamethasone ingestion in all study groups; this period of maximal biological action of dexamethasone was associated with peak plasma leptin levels. The peak dexamethasone-stimulated plasma leptin responses ({\%} baseline, ±SEM) were 188±18.7{\%} among healthy controls, 180±13.8{\%} among new DM patients, and 127±10.5{\%} (P<0.01) in chronic DM patients. Following dexamethasone ingestion, plasma glucose remained stable in the control and new DM groups but increased by 240{\%} in the chronic DM patients; in contrast, plasma insulin increased significantly in controls and new DM patients but not in patients with chronic DM. These results indicate that plasma leptin responses to secretagogue are preserved in newly diagnosed diabetes patients but markedly attenuated in patients with long-standing diabetes, who also were unable to augment insulin secretion during glucocorticoid treatment. Thus, defective glucocorticoid augmentation of plasma leptin, probably related to β-cell failure, may be a novel chronic complication of diabetes. Theoretically, such a defect could contribute to the obesity and insulin resistance associated with diabetes. Copyright (C) 2000 Elsevier Science Inc.",
author = "Samuel Dagogo-Jack and Jianmei Liu and Hasan Askari and Gunjan Tykodi and Indira Umamaheswaran",
year = "2000",
month = "12",
day = "16",
doi = "10.1016/S1056-8727(00)00090-8",
language = "English (US)",
volume = "14",
pages = "327--332",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Impaired leptin response to glucocorticoid as a chronic complication of diabetes

AU - Dagogo-Jack, Samuel

AU - Liu, Jianmei

AU - Askari, Hasan

AU - Tykodi, Gunjan

AU - Umamaheswaran, Indira

PY - 2000/12/16

Y1 - 2000/12/16

N2 - Leptin has anorectic, anti-obesity, and insulin-sensitizing properties. We recently reported subnormal responses to the leptin secretagogue dexamethasone in diabetes (DM). To determine whether this defect precedes or follows the occurrence of diabetes, we have studied 37 adults: 11 with type 2 DM diagnosed within 6 months prior to study, 16 with chronic (≥20 years) DM, and 10 healthy controls. After baseline measurements, subjects ingested dexamethasone (4 mg), followed by blood sampling 16 and 40 h later. Nadir plasma cortisol levels (<2.5 mg/dl) occurred 16 h after dexamethasone ingestion in all study groups; this period of maximal biological action of dexamethasone was associated with peak plasma leptin levels. The peak dexamethasone-stimulated plasma leptin responses (% baseline, ±SEM) were 188±18.7% among healthy controls, 180±13.8% among new DM patients, and 127±10.5% (P<0.01) in chronic DM patients. Following dexamethasone ingestion, plasma glucose remained stable in the control and new DM groups but increased by 240% in the chronic DM patients; in contrast, plasma insulin increased significantly in controls and new DM patients but not in patients with chronic DM. These results indicate that plasma leptin responses to secretagogue are preserved in newly diagnosed diabetes patients but markedly attenuated in patients with long-standing diabetes, who also were unable to augment insulin secretion during glucocorticoid treatment. Thus, defective glucocorticoid augmentation of plasma leptin, probably related to β-cell failure, may be a novel chronic complication of diabetes. Theoretically, such a defect could contribute to the obesity and insulin resistance associated with diabetes. Copyright (C) 2000 Elsevier Science Inc.

AB - Leptin has anorectic, anti-obesity, and insulin-sensitizing properties. We recently reported subnormal responses to the leptin secretagogue dexamethasone in diabetes (DM). To determine whether this defect precedes or follows the occurrence of diabetes, we have studied 37 adults: 11 with type 2 DM diagnosed within 6 months prior to study, 16 with chronic (≥20 years) DM, and 10 healthy controls. After baseline measurements, subjects ingested dexamethasone (4 mg), followed by blood sampling 16 and 40 h later. Nadir plasma cortisol levels (<2.5 mg/dl) occurred 16 h after dexamethasone ingestion in all study groups; this period of maximal biological action of dexamethasone was associated with peak plasma leptin levels. The peak dexamethasone-stimulated plasma leptin responses (% baseline, ±SEM) were 188±18.7% among healthy controls, 180±13.8% among new DM patients, and 127±10.5% (P<0.01) in chronic DM patients. Following dexamethasone ingestion, plasma glucose remained stable in the control and new DM groups but increased by 240% in the chronic DM patients; in contrast, plasma insulin increased significantly in controls and new DM patients but not in patients with chronic DM. These results indicate that plasma leptin responses to secretagogue are preserved in newly diagnosed diabetes patients but markedly attenuated in patients with long-standing diabetes, who also were unable to augment insulin secretion during glucocorticoid treatment. Thus, defective glucocorticoid augmentation of plasma leptin, probably related to β-cell failure, may be a novel chronic complication of diabetes. Theoretically, such a defect could contribute to the obesity and insulin resistance associated with diabetes. Copyright (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033663710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033663710&partnerID=8YFLogxK

U2 - 10.1016/S1056-8727(00)00090-8

DO - 10.1016/S1056-8727(00)00090-8

M3 - Article

C2 - 11120457

AN - SCOPUS:0033663710

VL - 14

SP - 327

EP - 332

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 6

ER -